A cascade C-H activation/2-fold annulation of 2-aryloxazolines with pyridotriazoles has been achieved employing Rh-catalysis to afford heteroaryl-tethered oxazoloisoquinolinones. The synergistic annulations, functional group tolerance, and late-stage skeletal editing of the bioactive scaffolds are the salient practical features.
No takes yet. Share an insight, caveat, or question.
Basak et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: